Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Impedimed Limited ( (AU:IPD) ) has provided an update.
ImpediMed reported record Q2 FY26 revenue of $3.9 million, ARR of $14.4 million, and $18.9 million in cash, while expanding SOZO unit sales and achieving near-national lymphoedema reimbursement, supporting commercial pilots in heart health and launches in wellness and weight management with a strong U.S. pipeline. Management emphasized the SOZO Pro rollout, strategic conference presence, and discussions with partners to accelerate growth across BCRL, heart failure, and weight-loss indications, suggesting improving operating momentum despite ongoing cash outflows.
The most recent analyst rating on (AU:IPD) stock is a Sell with a A$0.03 price target. To see the full list of analyst forecasts on Impedimed Limited stock, see the AU:IPD Stock Forecast page.
More about Impedimed Limited
ImpediMed Limited operates in digital health, providing SOZO bioimpedance spectroscopy devices for breast-cancer-related lymphoedema, heart failure monitoring, and body composition, with commercial efforts across U.S. hospitals and weight management markets.
Average Trading Volume: 1,505,358
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$67.28M
For a thorough assessment of IPD stock, go to TipRanks’ Stock Analysis page.